Trial Profile

A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin; Cisplatin; Cobalamin; Dexamethasone; Folic acid
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms MK-3475-189/KEYNOTE-189
Sponsors Merck Sharp & Dohme Corp.

12 Sep 2023 Results of pooled analysis of 5-year outcomes , from KEYNOTE-407 China Extension, KEYNOTE-407, KEYNOTE-189 and KEYNOTE-189 Japan extension presented at the 24th World Conference on Lung Cancer
13 Jul 2023 Status changed from active, no longer recruiting to completed.
15 May 2023 Planned End Date changed from 25 May 2023 to 22 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com